argenx (ARGX) Q1 2026 earnings summary

Executive summary

• New CEO Karen Massey affirmed commitment to Vision 2030, targeting 2.5x more VYVGART patients, tripling indications, and five late-stage molecules by decade's end.

• Achieved $1.3 billion in global product net sales for Q1 2026, up 63% year-over-year, marking the 17th consecutive quarter of VYVGART growth.

• Expanded global presence with a new affiliate in China and leadership changes, including a new CEO and Board Chair.

• VYVGART continues strong growth in MG and CIDP, with label expansions in seronegative, ocular, and pediatric MG anticipated.

• Pipeline advances include empasiprubart (C2 inhibitor) nearing phase III readout in MMN and expansion into rheumatology with myositis and Sjögren's trials.

Financial highlights

• Q1 2026 product net sales reached $1.3 billion, up 63% year-over-year; U.S. sales were $1.1 billion.

• Operating profit was $394 million with a 30% margin, up 183% year-over-year.

• Net profit for Q1 2026 was $366 million, up 116% from $169 million in Q1 2025.

• Basic EPS increased to $5.90 from $2.78 year-over-year.

• Cash, cash equivalents, and current financial assets totaled $4.9 billion as of March 31, 2026, up from $4.4 billion at year-end 2025.

Outlook and guidance

• Full-year expectations unchanged; growth trajectory consistent with prior years.

• Margin expansion expected to continue quarterly and annually, supported by strong revenue growth and operating leverage.

• PDUFA action date for anti-AChR antibody negative gMG is May 10, 2026.

• Topline results from ALKIVIA (myositis) expected Q3 2026; EMPASSION (MMN) topline results expected Q4 2026.

• VYVGART SC autoinjector launch planned for 2027 for all approved indications.